Volition(VNRX) - 2024 Q4 - Annual Results

FORM 8-K Filing Information This section details the foundational information for the Form 8-K filing, including registrant identification and securities status Registrant Information This section provides the fundamental identification details for VolitionRx Limited as the registrant, including its legal and operational addresses, and contact information for the current report filing - Registrant: VolitionRx Limited[1] - Jurisdiction of Incorporation: Delaware[1] - Principal Executive Offices: 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014[1] Filing Status and Securities This part clarifies the company's filing status, indicating it is not an emerging growth company, and lists the securities registered under Section 12(b) of the Exchange Act - The registrant is not an emerging growth company[3] Securities Registered Pursuant to Section 12(b) of the Act | Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, par value $0.001 per share | VNRX | NYSE American, LLC | Item 2.02. Results of Operations and Financial Condition This section reports the announcement of VolitionRx Limited's financial performance and business updates for the quarter and fiscal year ended December 31, 2024 Announcement of Financial Results VolitionRx Limited announced its financial results and business updates for the quarter and fiscal year ended December 31, 2024, via a press release issued on March 31, 2025. The company also confirmed a conference call to discuss these results - VolitionRx Limited issued a press release on March 31, 2025, announcing financial results and business updates for Q4 and fiscal year ended December 31, 2024[6] - A conference call was scheduled for March 31, 2025, at 4:30 p.m. U.S. Eastern Time[6] - The press release is furnished as Exhibit 99.1 and is incorporated by reference[6] Item 9.01. Financial Statements and Exhibits This section details the supplementary documents and data files included as exhibits to the Form 8-K filing Exhibits List This section lists the exhibits accompanying the Form 8-K filing, primarily the press release detailing the financial results and an interactive data file Exhibits Furnished with Form 8-K | Exhibit Number | Description | | :------------- | :----------------------------------------------------------------------- | | 99.1 | Press Release of VolitionRx Limited, dated March 31, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | SIGNATURE This section confirms the official authorization and signing of the Form 8-K report by the company's executive leadership Report Authorization The Form 8-K report was duly signed on behalf of VolitionRx Limited by its Chief Executive Officer & President, Cameron Reynolds, on March 31, 2025, confirming compliance with Securities Exchange Act requirements - The report was signed on March 31, 2025[12] - Signed by Cameron Reynolds, Chief Executive Officer & President of VolitionRx Limited[12]